- Case report
- Open Access
Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction
Journal of Cardiothoracic Surgery volume 5, Article number: 9 (2010)
This the case of a 63 year-old man with end-stage renal disease (on chronic hemodialysis), unstable angina and significantly impaired myocardial contractility with low left ventricular ejection fraction, who underwent off-pump one vessel coronary bypass surgery. Combined continuous levosimendan and norepinephrine infusion (at 0.07 μg/kg/min and 0.05 μg/kg/min respectively) started immediately after anesthesia induction and continued for 24 hours. The levosimendan/norepinephrine combination helped maintain an appropriate hemodynamic profile, thereby contributing to uneventful completion of surgery and postoperative hemodynamic stability. Although levosimendan is considered contraindicated in ESRD patients, this case report suggests that combined perioperative levosimendan/norepinephrine administration can be useful in carefully selected hemodialysis patients with impaired myocardial contractility and ongoing myocardial ischemia, who undergo off-pump myocardial revascularization surgery.
Levosimendan (OR 1259), the levo-isomer of racemic simendan  is a pharmacologic agent indicated for treatment of non-compensated heart failure. Levosimendan enhances myocardial contractility without increasing myocardial oxygen consumption [2, 3] through two different mechanisms: (A) calcium-dependent binding to cardiac troponin C, thereby enhancing the calcium sensitivity of cardiac contractile proteins [3, 4] and improving myocardial contractility, and (B) opening of ATP-dependent potassium channels in vascular smooth muscle, resulting in venous, arterial and coronary vasodilation [5–8], thereby reducing myocardial preload and afterload.
Levosimendan is 98% albumin-bound, its volume of distribution is 0.4 L/kg, plasma half life is 1 hour , and plasma clearance is 3 ml/kg/min [10, 11]. Peak plasma concentrations occur 12 minutes after a bolus dose or 4 hours after starting a continuous infusion without a bolus. Levosimendan is extensively metabolized in the liver, is eliminated mainly by conjugation and excretion in urine and feces, and its elimination half-life is 1 hour . After IV levosimendan administration, 5% of the drug is reduced in the small bowel to OR-1855, which is reabsorbed to the systemic circulation, and is then metabolized to OR-1896, which is pharmacologically active and produces a hemodynamic profile comparable to the parent-drug. OR-1896 is only 40% protein-bound, its peak plasma concentration is observed 1-4 days after levosimendan infusion ends , its half life is 80 hours, and it is responsible for the extended (7-9 days) duration of levosimendan clinical action [5, 12–14].
Levosimendan is not dialyzable. In contrast, OR-1855 and OR-1896 are dialyzable, but their dialysis clearance is very slow (8-23 ml/minute). Consequently, the net effect of a 4-hour hemodialysis session on exposure to active metabolites is limited , and the AUCs for OR-1855 and OR-1896 are increased by 170% in hemodialysis patients. Although the Levosimendan package insert  states that levosimendan should not be used in ESRD patients, there is one case report of postoperative use , but no reports of intraoperative levosimendan use in hemodialysis patients. In this case report we describe a hemodialysis patient with severe CAD, ongoing myocardial ischemia despite maximal medical therapy, low LVEF and severe bilateral ICA stenosis. The patient received a 24-hour continuous IV levosimendan/norepinephrine infusion during and after OPCAB surgery, with very satisfactory results: myocardial contractility, CO, CI, SvO2 and INVOS markedly improved, and there was no hypotension or exacerbation of myocardial ischemia.
A 63 year-old Caucasian man with unstable angina and chronic renal failure underwent one vessel OPCAB. Past medical history included smoking 2 packs per day for 40 years, hypertension, IDDM treated with insulin for 15 years, PVD with claudication and bilateral ICA stenosis, ESRD (Cr: 8.4 mg/dL, BUN: 199 mg/dL) which had been attributed to long-standing poorly controlled hypertension, and was treated with periodic (every other day) hemodialysis for 6 years, and sick sinus syndrome. He had a pacemaker (programmed in DDD mode with baseline HR set at 60/minute) inserted three years before this myocardial revascularization procedure, but the pacemaker was turned off immediately after anesthesia induction. He also had intermittent claudication, with preoperative angiography revealing significant right iliac and left femoral artery stenosis, extensive abdominal aorta calcification and 80% bilateral ICA stenosis. Coronary angiography revealed 3-vessel disease, with 80% mid-LAD stenosis, complete proximal and distal LCX occlusion with retrograde filling from the LAD, and complete ostial RCA occlusion. Transthoracic echocardiography revealed LV dilatation with akinetic basal inferior and basal posterior LV wall, hypokinetic medial posterior LV wall, LVEF estimated at 25-30%, moderate mitral regurgitation and pulmonary hypertension (estimated peak PA pressure 58 mmHg). In the last week before surgery, the patient had difficulty completing hemodialysis sessions due to serious hypotension, and experienced unstable angina, while under maximal medical therapy with nitrates (transdermal glyceryl trinitrate 10 mg per 24 hours), ACE inhibitors (p.o. enalapril 10 mg per day) and aspirin (p.o. 325 mg per day). Because of his unstable condition, we decided to proceed with myocardial revascularization only, and consider surgical treatment of bilateral ICA stenosis later. Furthermore, we chose the OPCAB technique, in order to lower the risk of adverse cerebral events and avoid the undesirable consequences of cardiopulmonary bypass. Monitoring included, in addition to the standard monitors mandated by the American Society of Anesthesiologists, invasive blood pressure through a right radial arterial line, CVP, PA and PAOP pressures through a PA catheter, which was inserted immediately after induction of anesthesia and was removed on the 2nd postoperative day. We also used INVOS (Cerebral Oximeter System, Somanetics), with sensors attached to the patient's forehead, to monitor adequacy of cerebral perfusion, and TEE to monitor myocardial contractility. Anesthesia induction was uneventful, without any hemodynamic derangement. Mean arterial pressure was maintained at 60 mmHg or higher, while the PA catheter revealed pulmonary hypertension (SPAP: 56 mmHg, PAOP: 18 mmHg, CVP: 18 mmHg, CO: 2.8 L/min, CI: 1.6 L/m2/min SvO2 49%, SVR 1114). As direct visualization of the heart confirmed severely impaired myocardial contractility with abnormal distension of both ventricles, we decided to start inotropic support using a combined levosimendan/norepinephrine infusion in an attempt to improve myocardial function and increase cardiac output, while avoiding myocardial ischemia and hypotension. The decision to use a levosimendan/norepinephrine combination was based on the need to (A) improve myocardial contractility and cardiac output without increasing myocardial oxygen consumption, and (B) avoid hypotension, which could aggravate myocardial and brain ischemia. Because of hypoalbuminemia, we started IV levosimendan infusion at only 0.07 μg/kg/min, while IV norepinephrine infusion started at 0.05 μg/kg/min and was titrated to effect. Baseline INVOS values were very low before anesthesia induction (42 on the left, 37 on the right side) and increased only slightly after anesthesia induction (45 on the left, 43 on the right side). However, thirty minutes after levosimendan infusion started, CO, CI and SvO2 improved significantly (to 3.6 L/min, 2.1 L/m2/min and 70% respectively), LVEF increased to 50% and INVOS also increased significantly (to 59 on the left, 53 on the right). Despite the need to gradually increase norepinephrine dose to 0.15 μg/kg/min, in order to maintain MAP >60 mmHg, CI and SvO2 continued to rise, while CVP, PA and PAOP declined slightly over the ensuing 3 hours (while surgery was still underway), and this improvement persisted during the entire postoperative period (table 1). Accidental intraoperative rupture of the very thin anterior RV wall resulted in hemodynamic collapse, requiring prompt, rapid administration of 5 units of red blood cells, 2 units of FFP and addition of epinephrine infusion at 0.07 μg/kg/min. Hypotension lasted approximately 30 minutes, until the RV wall rupture was securely corrected (without requiring extracorporeal circulation). Postoperatively, the patient was transferred to the ICU, where levosimendan infusion continued for 24 hours and norepinephrine continued for 40 hours. The patient was extubated on POD 1, and had uneventful hemodialysis a few hours after extubation. Detailed postoperative neurologic examination did not reveal any neurologic deficits. Vital signs remained stable postoperatively, except for an episode of hypotension shortly after hemodialysis on POD 5. This hypotensive event resolved with volume loading, and was attributed to pericardial effusion, which delayed discharge from the hospital until POD 12. Three months later, the patient was in good condition, had a normal life and continued hemodialysis three times/week without any problems. Follow-up echocardiography 4 months after the operation showed somewhat improved myocardial contractility, with LVEF estimated at 40%, mild mitral regurgitation and estimated peak pulmonary artery pressure at 35 mmHg. Now, three years later, he is still alive and doing remarkably well.
Levosimendan is a newer therapeutic agent for treatment of cardiac failure , is generally well tolerated, and its main side effects are usually due to vasodilation. Although levosimendan has been administered to patients with mild to moderate renal disease without serious adverse consequences , we could find only one published case of postoperative (but not intraoperative) levosimendan administration in a hemodialysis patient . Despite the absence of published data, we decided to use levosimendan in our patient, because he had significantly impaired LV function, low CO, CI and SvO2, and evidence of impaired cerebral oxygenation, as measured by INVOS. We therefore needed to improve myocardial contractility, CO, CI and SvO2 without increasing myocardial oxygen consumption and without hypotension, which could be detrimental, due to severe bilateral ICA stenosis. Under the circumstances, combined levosimendan/norepinephrine use was a reasonable choice: levosimendan improves myocardial contractility without increasing myocardial oxygen consumption [15–17], while norepinephrine has desirable inotropic and vasopressor properties. Use of IABP could also be a reasonable option, but insertion of IABP in this particular patient would be problematic due to extensive peripheral arterial (aortic, iliac and femoral) calcification and stenosis, and could further compromise lower extremity circulation. Dobutamine, milrinone and/or epinephrine could also improve myocardial contractility, but would likely increase myocardial oxygen consumption, and thereby exacerbate myocardial ischemia. In our case, the levosimendan/norepineprhine combination worked as predicted, conferred significant hemodynamic improvement (despite unexpected surgical complications necessitating rapid intraoperative RBC and FFP transfusion) and facilitated completion of the OPCAB procedure without need for extracorporeal circulation. Thus the patient benefitted from improved myocardial contractility, increased CO, CI and SvO2 and reduced CVP and PAOP, and these beneficial changes lasted for several days after levosimendan infusion stopped. We believe that the effectiveness of levosimendan at this low dose (0.07 μg/kg/min) was due to reduced protein binding because of hypoalbuminemia (albumin plasma level was 3.1 mg/dL in this case). In addition, the use of a low levosimendan dose, the combination with norepinephrine and close monitoring, in an attempt to avoid or promptly treat hypotension, all likely contributed to hemodynamic stability in this case. In conclusion, this case report suggests that combined levosimedan/norepinephrine IV infusion is a reasonable inotropic support option in patients with heart failure and ongoing myocardial ischemia, even in the presence of end-stage renal disease and severe bilateral internal carotid artery stenosis.
Written informed consent was obtained from the patient for publication of this report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- ACE inhibitors:
Angiotensin-Converting Enzyme Inhibitors
Coronary Artery Bypass Grafting
Coronary Artery Disease
Chronic Renal Failure
Central Venous Pressure
End-Stage Renal Disease
Fresh Frozen Plasma
Intra-Aortic Balloon Pump
Internal Carotid Artery
Insulin-Dependent Diabetes Mellitus
IN Vivo Optical Spectroscopy
Left Anterior Descending
Left Circumflex Coronary Artery
Left-ventricular ejection fraction
Mean Arterial Pressure
Off pump coronary artery by-pass
Pulmonary Artery Occlusion Pressure
Peripheral Vascular Disease
Red Blood Cells
Right Coronary Artery
- SvO2 :
Mixed Venous Oxygen Saturation
Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkhoff D: Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther. 1996, 279: 120-127.
Levijoki J, Pollesello P, Kaivola J, Tilgmann C, Sorsa T, Annila A, Kilpelainen I, Haikala H: Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol. 2000, 32: 479-491. 10.1006/jmcc.1999.1093.
Simdax - Levosimendan 2.5 mg/mL injection concentrate - Data Sheet. 2009, New Zealand, New Zealand Medicines and Medical Devices Safety Authority, a Business Unit of the Ministry of Health, 1-10-2010., [http://www.medsafe.govt.nz/profs/Datasheet/s/Simdaxinj.htm]
Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M: Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007, 297: 1883-1891. 10.1001/jama.297.17.1883.
Bowman P, Haikala H, Paul RJ: Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1999, 288: 316-325.
Keheninen P, Haikala H: Increases in diastolic coronary flow by Levosimendan and pinacidil are differently mediated through opening of the ATP-sensitive potassium channels. J Amer Coll Cardiol. 1998, 31: 154-
Pataricza J, Hohn J, Petri A, Balogh A, Papp JG: Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000, 52: 213-217. 10.1211/0022357001773715.
Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther. 1997, 283: 375-383.
Kivikko M, Lehtonen L: Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des. 2005, 11: 435-455. 10.2174/1381612053382043.
Puttonen J, Kantele S, Ruck A, Ramela M, Hakkinen S, Kivikko M, Pentikainen PJ: Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment. J Clin Pharmacol. 2008, 48: 445-454. 10.1177/0091270007313390.
Antila S, Kivikko M, Lehtonen L, Eha J, Heikkila A, Pohjanjousi P, Pentikainen PJ: Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol. 2004, 57: 412-415. 10.1111/j.1365-2125.2003.02043.x.
McLean AS, Huang SJ, Nalos M, Ting I: Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol. 2005, 46: 830-835. 10.1097/01.fjc.0000189076.71730.f1.
Raftopoulos SC: Levosimendan following coronary artery bypass grafting in a patient with end-stage renal failure: a case report. Crit Care Resusc. 2004, 6: 109-112.
Sandell EP, Antila S, Koistinen IL: The effects of renal failure on the pharmacokinetics of levosimendan [abstract]. 1st Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). 1995
Antila S, Honkanen T, Lehtonen L, Neuvonen PJ: The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Int J Clin Pharmacol Ther. 1998, 36: 446-449.
Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB: Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995, 27: 1859-1866. 10.1016/0022-2828(95)90009-8.
Lehtonen L, Mills-Owens P, Akkila J: Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol. 1995, 26 (Suppl 1): S70-S76.
This work was supported solely by department funds. All authors declare that they have no competing interests.
GP supervised intraoperative and postoperative anesthesia care, conceived the study and revised manuscript, NB assisted with the operation, participated in postoperative patient care and collected data, PT provided intraoperative and postoperative anesthesia care and collected data, SN performed the operation, directed postoperative care and revised manuscript, MK did data interpretation, wrote and revised manuscript. All authors have read and approved the final manuscript.
About this article
Cite this article
Papadopoulos, G., Baikoussis, N.G., Tzimas, P. et al. Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction. J Cardiothorac Surg 5, 9 (2010). https://doi.org/10.1186/1749-8090-5-9
- Hemodialysis Patient
- Myocardial Contractility
- Myocardial Oxygen Consumption
- Anesthesia Induction